Renal cancer

The Lancet

Volumn 387, Issue 10021, 2016, Pages 894-906

  Capitanio, Umberto ^a   Montorsi, Francesco ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALECTOMY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER INCIDENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; KIDNEY BIOPSY; KIDNEY CARCINOMA; LYMPH NODE DISSECTION; META ANALYSIS (TOPIC); METASTASIS; MINIMALLY INVASIVE PROCEDURE; NEPHRECTOMY; NEPHRON SPARING SURGERY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; SYSTEMATIC REVIEW (TOPIC); THROMBECTOMY; TUMOR BIOPSY; AGED; DIAGNOSTIC IMAGING; FEMALE; GENETICS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

AGED; DIAGNOSTIC IMAGING; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEPHRECTOMY;

EID: 84959483228     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00046-X     Document Type: Conference Paper

References (142)

1. C Ellimoottil, KA Greco, S Hart et al. New modalities for evaluation and surveillance of complex renal cysts J Urol 192 2014 1604 1611
2. S Shah, T Watnick, MG Atta Not all renal cysts are created equal Lancet 376 2010 1024
3. R Siegel, J Ma, Z Zou, A Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
4. JSI Ferlay, M Ervik, R Dikshit et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 http://globocan.iarc.fr 2013 (accessed Jan 1, 2015).
5. F Levi, J Ferlay, C Galeone et al. The changing pattern of kidney cancer incidence and mortality in Europe BJU Int 101 2008 949 958
6. WH Chow, WM Linehan, SS Devesa Re: rising incidence of small renal masses: a need to reassess treatment effect J Natl Cancer Inst 99 2007 569 570
7. JM Hollingsworth, DC Miller, S Daignault, BK Hollenbeck Rising incidence of small renal masses: a need to reassess treatment effect J Natl Cancer Inst 98 2006 1331 1334
8. HG Welch, LM Schwartz, S Woloshin Are increasing 5-year survival rates evidence of success against cancer? JAMA 283 2000 2975 2978
9. RP Theis, SM Dolwick Grieb, D Burr, T Siddiqui, NR Asal Smoking, environmental tobacco smoke, and risk of renal cell cancer: a population-based case-control study BMC Cancer 8 2008 387
10. IA Deckers, PA van den Brandt, M van Engeland et al. Polymorphisms in genes of the renin-angiotensin-aldosterone system and renal cell cancer risk: interplay with hypertension and intakes of sodium, potassium and fluid Int J Cancer 136 2015 1104 1116
11. A Zucchetto, L Dal Maso, A Tavani et al. History of treated hypertension and diabetes mellitus and risk of renal cell cancer Ann Oncol 18 2007 596 600
12. G Corrao, L Scotti, V Bagnardi, R Sega Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis Curr Drug Saf 2 2007 125 133
13. A Gati, S Kouidhi, R Marrakchi et al. Obesity and renal cancer: Role of adipokines in the tumor-immune system conflict Oncoimmunology 3 2014 e27810
14. A Bergström, CC Hsieh, P Lindblad, CM Lu, NR Cook, A Wolk Obesity and renal cell cancer - a quantitative review Br J Cancer 85 2001 984 990
15. S Karami, SE Daugherty, MP Purdue A prospective study of alcohol consumption and renal cell carcinoma risk Int J Cancer 137 2015 238 242
16. S Rohrmann, J Linseisen, K Overvad et al. Meat and fish consumption and the risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition Int J Cancer 136 2015 E423 E431
17. B Ljungberg, SC Campbell, HY Choi et al. The epidemiology of renal cell carcinoma Eur Urol 60 2011 615 621
18. B Shuch, A Amin, AJ Armstrong et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity Eur Urol 67 2015 85 97
19. JR Srigley, B Delahunt, JN Eble the ISUP Renal Tumor Panel The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia Am J Surg Pathol 37 2013 1469 1489
20. M Bianchi, M Sun, C Jeldres et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis Ann Oncol 23 2012 973 980
21. R Srinivasan, CJ Ricketts, C Sourbier, WM Linehan New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease Clin Cancer Res 21 2015 10 17
22. LE Moore, ML Nickerson, P Brennan et al. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors PLoS Genet 7 2011 e1002312
23. J Brugarolas PBRM1 and BAP1 as novel targets for renal cell carcinoma Cancer J 19 2013 324 332
24. Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma Nature 499 2013 43 49
25. I Ibragimova, ME Maradeo, E Dulaimi, P Cairns Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC Epigenetics 8 2013 486 493
26. L Gossage, T Eisen, ER Maher VHL, the story of a tumour suppressor gene Nat Rev Cancer 15 2015 55 64
27. PG Dharmawardana, A Giubellino, DP Bottaro Hereditary papillary renal carcinoma type I Curr Mol Med 4 2004 855 868
28. E Perdeaux, J Solly Birt-Hogg-Dubé syndrome JAMA 309 2013 1460
29. B Shuch, CJ Ricketts, CD Vocke et al. Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer J Urol 189 2013 430 435
30. P Sooriakumaran, CJ Anderson Everolimus for renal angiomyolipoma in tuberous sclerosis Lancet 381 2013 783 785
31. E Sacco, F Pinto, F Sasso et al. Paraneoplastic syndromes in patients with urological malignancies Urol Int 83 2009 1 11
32. SL Hofbauer, M de Martino, C Seemann et al. Associations between presenting symptoms, clinicopathological parameters, and prognosis in a contemporary series of patients with renal cell carcinoma Korean J Urol 55 2014 505 510
33. BBK Ljungberg, A Bex, S Canfield et al. Guidelines on renal cell carcinoma, update http://uroweb.org/wp-content/uploads/10-Renal-Cell-Carcinoma-LR.pdf April 2014 (accessed July 15, 2015).
34. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer 2 http://www.nccn.org/professionals/physician-gls/pdf/kidney.pdf 2014 (accessed July 15, 2015).
35. American Urological Association Follow-up for clinically localized renal neoplasms: AUA guideline 2013 https://www.auanet.org/common/pdf/education/clinical-guidance/Renal-Cancer-Followup.pdf April 2013 (accessed July 15, 2015).
36. S Hilton, LP Jones Recent advances in imaging cancer of the kidney and urinary tract Surg Oncol Clin N Am 23 2014 863 910
37. B Ljungberg, K Bensalah, S Canfield et al. EAU guidelines on renal cell carcinoma: 2014 update Eur Urol 67 2015 913 924
38. CH Muselaers, OC Boerman, E Oosterwijk, JF Langenhuijsen, WJ Oyen, PF Mulders Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma Eur Urol 63 2013 1101 1106
39. CR Divgi, RG Uzzo, C Gatsonis et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial J Clin Oncol 31 2013 187 194
40. JJ Tomaszewski, RG Uzzo, MC Smaldone Heterogeneity and renal mass biopsy: a review of its role and reliability Cancer Biol Med 11 2014 162 172
41. MW Ball, SM Bezerra, MA Gorin et al. Grade heterogeneity in small renal masses: potential implications for renal mass biopsy J Urol 193 2015 36 40
42. A Volpe, A Finelli, IS Gill et al. Rationale for percutaneous biopsy and histologic characterisation of renal tumours Eur Urol 62 2012 491 504
43. MJ Leveridge, A Finelli, JR Kachura et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy Eur Urol 60 2011 578 584
44. S Baillargeon-Gagné, C Jeldres, G Lughezzani et al. A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma BJU Int 105 2010 359 364
45. U Capitanio, C Terrone, A Antonelli et al. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function Eur Urol 67 2015 683 689
46. M Sun, F Abdollah, M Bianchi et al. Treatment management of small renal masses in the 21st century: a paradigm shift Ann Surg Oncol 19 2012 2380 2387
47. A Kutikov, BL Egleston, YN Wong, RG Uzzo Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram J Clin Oncol 28 2010 311 317
48. R Mehrazin, MC Smaldone, B Egleston et al. Is anatomic complexity associated with renal tumor growth kinetics under active surveillance? Urol Oncol 33 2015 167.e7 167.e12
49. RA Rendon Active surveillance as the preferred management option for small renal masses Can Urol Assoc J 4 2010 136 138
50. PM Pierorazio, MH Johnson, MW Ball et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry Eur Urol 2015 10.1016/j.eururo.2015.02.001 published online Feb 16.
51. PL Crispen, R Viterbo, EB Fox, RE Greenberg, DY Chen, RG Uzzo Delayed intervention of sporadic renal masses undergoing active surveillance Cancer 112 2008 1051 1057
52. R Mehrazin, MC Smaldone, A Kutikov et al. Growth kinetics and short-term outcomes of cT1b and cT2 renal masses under active surveillance J Urol 192 2014 659 664
53. MA Jewett, K Mattar, J Basiuk et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer Eur Urol 60 2011 39 44
54. NE Hoffmann, JC Bischof The cryobiology of cryosurgical injury Urology 60 suppl 1 2002 40 49
55. K Katsanos, L Mailli, M Krokidis, A McGrath, T Sabharwal, A Adam Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours Cardiovasc Intervent Radiol 37 2014 427 437
56. DA Kunkle, BL Egleston, RG Uzzo Excise, ablate or observe: the small renal mass dilemma - a meta-analysis and review J Urol 179 2008 1227 1233
57. RJ Motzer, E Jonasch, N Agarwal et al. Kidney Cancer, Version 3.2015: featured updates to the NCCN guidelines J Natl Compr Canc Netw 13 2015 151 159
58. JM Woldrich, K Palazzi, SP Stroup et al. Trends in the surgical management of localized renal masses: thermal ablation, partial and radical nephrectomy in the USA, 1998-2008 BJU Int 111 2013 1261 1268
59. DA Gervais, FJ McGovern, RS Arellano, WS McDougal, PR Mueller Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors AJR Am J Roentgenol 185 2005 64 71
60. RH Thompson, T Atwell, G Schmit et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses Eur Urol 67 2015 252 259
61. A Kutikov, MC Smaldone, RG Uzzo Focal therapy for treatment of the small renal mass: dealer's choice or a therapeutic gamble? Eur Urol 67 2015 260 261
62. M Crépel, C Jeldres, M Sun et al. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma Urology 76 2010 883 888
63. M Crépel, C Jeldres, P Perrotte et al. Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment Urology 75 2010 271 275
64. H Van Poppel, L Da Pozzo, W Albrecht et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma Eur Urol 59 2011 543 552
65. E Scosyrev, EM Messing, R Sylvester, S Campbell, H Van Poppel Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904 Eur Urol 65 2014 372 377
66. BR Lane, SC Campbell, S Demirjian, AF Fergany Surgically induced chronic kidney disease may be associated with a lower risk of progression and mortality than medical chronic kidney disease J Urol 189 2013 1649 1655
67. WC Huang, EB Elkin, AS Levey, TL Jang, P Russo Partial nephrectomy versus radical nephrectomy in patients with small renal tumors - is there a difference in mortality and cardiovascular outcomes? J Urol 181 2009 55 61
68. PI Karakiewicz, A Briganti, FK Chun et al. Multi-institutional validation of a new renal cancer-specific survival nomogram J Clin Oncol 25 2007 1316 1322
69. L Zini, P Perrotte, U Capitanio et al. Radical versus partial nephrectomy: effect on overall and noncancer mortality Cancer 115 2009 1465 1471
70. C Terrone, A Volpe Can emerging level 1 evidence "discourage" elective nephron-sparing surgery for small renal tumors? Eur Urol 59 2011 553 555
71. KN Babaian, MM Merrill, S Matin et al. Partial nephrectomy in the setting of metastatic renal cell carcinoma J Urol 192 2014 36 42
72. U Capitanio, L Zini, P Perrotte et al. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study Urology 72 2008 1090 1095
73. A Volpe, ML Blute, V Ficarra et al. Renal ischemia and function after partial nephrectomy: a collaborative review of the literature Eur Urol 68 2015 61 74
74. DJ Parekh, JM Weinberg, B Ercole et al. Tolerance of the human kidney to isolated controlled ischemia J Am Soc Nephrol 24 2013 506 517
75. MN Simmons, SP Hillyer, BH Lee, AF Fergany, J Kaouk, SC Campbell Functional recovery after partial nephrectomy: effects of volume loss and ischemic injury J Urol 187 2012 1667 1673
76. Y Funahashi, R Hattori, T Yamamoto, O Kamihira, K Kato, M Gotoh Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney Eur Urol 55 2009 209 215
77. H Van Poppel, L Da Pozzo, W Albrecht the European Organization for Research and Treatment of Cancer (EORTC) the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) the Southwest Oncology Group (SWOG) the Eastern Cooperative Oncology Group (ECOG) A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma Eur Urol 51 2007 1606 1615
78. BK Hollenbeck, DA Taub, DC Miller, RL Dunn, JT Wei National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology 67 2006 254 259
79. DC Miller, JM Hollingsworth, KS Hafez, S Daignault, BK Hollenbeck Partial nephrectomy for small renal masses: an emerging quality of care concern? J Urol 175 2006 853 857
80. RH Thompson, M Kaag, A Vickers et al. Contemporary use of partial nephrectomy at a tertiary care center in the United States J Urol 181 2009 993 997
81. V Ficarra, G Novara, S Secco et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery Eur Urol 56 2009 786 793
82. A Kutikov, RG Uzzo The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth J Urol 182 2009 844 853
83. MN Simmons, CB Ching, MK Samplaski, CH Park, IS Gill Kidney tumor location measurement using the C index method J Urol 183 2010 1708 1713
84. G Sivarajan, GB Taksler, D Walter, CP Gross, RE Sosa, DV Makarov The Effect of the Diffusion of the Surgical Robot on the Hospital-level Utilization of Partial Nephrectomy Med Care 53 2015 71 78
85. JE Choi, JH You, DK Kim, KH Rha, SH Lee Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta-analysis Eur Urol 67 2015 891 901
86. C Gratzke, M Seitz, F Bayrle et al. Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma BJU Int 104 2009 470 475
87. AK Hemal, A Kumar, R Kumar, P Wadhwa, A Seth, NP Gupta Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison J Urol 177 2007 862 866
88. AD Asimakopoulos, R Miano, F Annino et al. Robotic radical nephrectomy for renal cell carcinoma: a systematic review BMC Urol 14 2014 75
89. HJ Bekema, S MacLennan, M Imamura et al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma Eur Urol 64 2013 799 810
90. U Capitanio, F Becker, ML Blute et al. Lymph node dissection in renal cell carcinoma Eur Urol 60 2011 1212 1220
91. JH Blom, H van Poppel, JM Maréchal the EORTC Genitourinary Tract Cancer Group Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881 Eur Urol 55 2009 28 34
92. UB Capitanio, F Becker, F Blute et al. Lymph node dissection in renal cell carcinoma Eur Urol 60 2011 1212 1220
93. A Bex, L Vermeeren, G de Windt, W Prevoo, S Horenblas, RA Olmos Feasibility of sentinel node detection in renal cell carcinoma: a pilot study Eur J Nucl Med Mol Imaging 37 2010 1117 1123
94. A Bex, L Vermeeren, W Meinhardt, W Prevoo, S Horenblas, RA Valdés Olmos Intraoperative sentinel node identification and sampling in clinically node-negative renal cell carcinoma: initial experience in 20 patients World J Urol 29 2011 793 799
95. A Haferkamp, PJ Bastian, H Jakobi et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup J Urol 177 2007 1703 1708
96. J Bellmunt, J Puente, J Garcia de Muro, N Lainez, C Rodríguez, I Duran SEOM clinical guidelines for the treatment of renal cell carcinoma Clin Transl Oncol 16 2014 1043 1050
97. FM Marincola, DE White, AP Wise, SA Rosenberg Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer J Clin Oncol 13 1995 1110 1122
98. C Coppin, F Porzsolt, A Awa, J Kumpf, A Coldman, T Wilt Immunotherapy for advanced renal cell cancer Cochrane Database Syst Rev 1 2005 CD001425.
99. RC Flanigan, SE Salmon, BA Blumenstein et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
100. GH Mickisch, A Garin, H van Poppel, L de Prijck, R Sylvester the European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970
101. RC Flanigan, G Mickisch, R Sylvester, C Tangen, H Van Poppel, ED Crawford Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 171 2004 1071 1076
102. BI Rini, SC Campbell The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy J Urol 177 2007 1978 1984
103. RJ Motzer, TE Hutson, P Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
104. B Escudier, T Eisen, WM Stadler et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
105. B Escudier, A Pluzanska, P Koralewski the AVOREN Trial investigators Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
106. B Escudier, J Bellmunt, S Négrier et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
107. BI Rini, S Halabi, JE Rosenberg et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
108. BI Rini, S Halabi, JE Rosenberg et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
109. BI Rini, J Bellmunt, J Clancy et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial J Clin Oncol 32 2014 752 759
110. G Hudes, M Carducci, P Tomczak the Global ARCC Trial Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
111. TE Hutson, B Escudier, E Esteban et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 32 2014 760 767
112. RJ Motzer, B Escudier, S Oudard the RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
113. CN Sternberg, ID Davis, J Mardiak et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
114. CN Sternberg, RE Hawkins, J Wagstaff et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update Eur J Cancer 49 2013 1287 1296
115. RJ Motzer, TE Hutson, D Cella et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 2013 722 731
116. RJ Motzer, TE Hutson, L McCann, K Deen, TK Choueiri Overall survival in renal-cell carcinoma with pazopanib versus sunitinib N Engl J Med 370 2014 1769 1770
117. TE Hutson, V Lesovoy, S Al-Shukri et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial Lancet Oncol 14 2013 1287 1294
118. BI Rini, B Escudier, P Tomczak et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
119. B Escudier, C Porta, P Bono et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study J Clin Oncol 32 2014 1412 1418
120. TE Delea, J Amdahl, J Diaz, HR Nakhaipour, MD Hackshaw Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States J Manag Care Spec Pharm 2015
121. DY Heng, W Xie, MM Regan et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study Lancet Oncol 14 2013 141 148
122. DY Heng, W Xie, MM Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
123. JN Ruiz, VR Belum, P Creel, A Cohn, M Ewer, ME Lacouture Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists Clin Genitourin Cancer 12 2014 341 347
124. G De Meerleer, V Khoo, B Escudier et al. Radiotherapy for renal-cell carcinoma Lancet Oncol 15 2014 e170 e177
125. P Singh, N Agarwal, SK Pal Sequencing systemic therapies for metastatic kidney cancer Curr Treat Options Oncol 16 2015 316
126. B Beuselinck, S Job, E Becht et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting Clin Cancer Res 21 2015 1329 1339
127. RJ Motzer, BI Rini, DF McDermott et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial J Clin Oncol 33 2015 1430 1437
128. RJ Motzer, D Nosov, T Eisen et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial J Clin Oncol 31 2013 3791 3799
129. A Mehta, G Sonpavde, B Escudier Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial Future Oncol 10 2014 1819 1826
130. RJ Motzer, C Porta, NJ Vogelzang et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial Lancet Oncol 15 2014 286 296
131. U Vaishampayan Cabozantinib as a novel therapy for renal cell carcinoma Curr Oncol Rep 15 2013 76 82
132. MS Gordon, M Hussey, RB Nagle et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317 J Clin Oncol 27 2009 5788 5793
133. J Brugarolas, Y Lotan, L Watumull, W Kabbani Sirolimus in metatastic renal cell carcinoma J Clin Oncol 26 2008 3457 3460
134. EORTC Randomized phase III trial comparing presurgical sunitinib followed by nephrectomy and sunitinib versus nephrectomy followed by sunitinib in patients with synchronous metastatic renal cell carcinoma http://www.eortc.be/protoc/Details.asp?Protocol=30073&T=2010 2010 (accessed July 15, 2015).
135. EM Messing, J Manola, G Wilding the Eastern Cooperative Oncology Group/Intergroup trial Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial J Clin Oncol 21 2003 1214 1222
136. G Pizzocaro, L Piva, M Colavita et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study J Clin Oncol 19 2001 425 431
137. JI Clark, MB Atkins, WJ Urba et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial J Clin Oncol 21 2003 3133 3140
138. JS Lam, O Shvarts, AS Belldegrun Kidney cancer management in 2004: an update for the practicing general urologist Curr Urol Rep 5 2004 1 3
139. DY Kim, JA Karam, CG Wood Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy World J Urol 32 2014 631 642
140. RH Breau, ML Blute Surgery for renal cell carcinoma metastases Curr Opin Urol 20 2010 375 381
141. P Russo, MF O'Brien Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy Urol Clin North Am 35 2008 679 686 viii.
142. S Dabestani, L Marconi, F Hofmann et al. Local treatments for metastases of renal cell carcinoma: a systematic review Lancet Oncol 15 2014 e549 e561